Now oncologists in the UK have found a two-pronged treatment – immunotherapy combined with guadecitabine, a novel experimental drug – can reverse a cancer’s resistance to immunotherapy.
Patients in the trial, from the Royal Marsden and University College London hospital, included those with lung, breast, prostate and bowel cancer. guadecitabine and pembrolizumab could help to tackle some of the resistance to immunotherapy we see in too many types of cancer. Pembrolizumab is an immune checkpoint inhibitor drug that has already proved successful in treating a range of cancers, including lung and skin cancers. However, tumours can develop resistance to it and some patients who initially benefit will eventually get sicker.
IMU Price at posting:
12.8¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)